Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms (NCT05748028)

Overview

This observational clinical study characterizes pain and autonomic symptoms in patients with Parkinson's disease (PD) and atypical Parkinsonian syndromes, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). The study investigates the prevalence, mechanisms, and impact of these non-motor symptoms on quality of life, addressing a critical gap in the understanding of these often underrecognized manifestations of neurodegenerative disorders["@nct"].

Overview

This observational clinical study characterizes pain and autonomic symptoms in patients with Parkinson's disease (PD) and atypical Parkinsonian syndromes, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). The study investigates the prevalence, mechanisms, and impact of these non-motor symptoms on quality of life, addressing a critical gap in the understanding of these often underrecognized manifestations of neurodegenerative disorders["@nct"].

Non-motor symptoms have emerged as a major determinant of quality of life in parkinsonian syndromes, often preceding motor symptoms by years and contributing significantly to disease burden. Among these, pain and autonomic dysfunction represent two of the most prevalent yet understudied non-motor manifestations, affecting the majority of patients throughout the disease course["@defaye2022"][@Chaudhuri2010].

Study Details

| Field | Value |
|-------|-------|
| NCT ID | NCT05748028 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, CBS, Atypical Parkinsonism |
| Enrollment | Target 200 participants |
| Primary Outcome | Prevalence and characteristics of pain and autonomic symptoms |

Scientific Rationale

Pain in Parkinsonian Syndromes

Pain is a common and underrecognized non-motor symptom that significantly impacts quality of life, functional capacity, and treatment outcomes in parkinsonian disorders. The pathogenesis of pain in these conditions is multifactorial, involving dopaminergic dysfunction, neuroinflammation, sensory pathway involvement, and secondary effects from motor symptoms[@defaye2022][@wu2019].

Prevalence

Pain affects a substantial proportion of patients across all parkinsonian syndromes:

• Parkinson's Disease: 30-80% of patients experience pain during their disease course, making it one of the most common non-motor symptoms
• Progressive Supranuclear Palsy: 50-70% of patients report significant pain, often related to axial rigidity and dystonia
• Multiple System Atrophy: Pain prevalence is similar to PSP, with additional contributions from autonomic dysfunction
• Corticobasal Syndrome: Pain is frequently related to asymmetric limb rigidity and dystonia

The pain experienced by patients with parkinsonian syndromes can be categorized into several distinct types:

• Related to rigidity, bradykinesia, and akinesia
• Often manifests as diffuse body aches or localized pain in joints
• Worsened by immobility and improved with dopaminergic therapy
• Common in neck, shoulders, lower back, and knees

• Characterized by burning, shooting, or electric shock-like sensations
• May result from nerve damage or central sensory pathway involvement
• Often less responsive to standard dopaminergic therapy
• May involve thalamic pain syndrome (central pain)

• Associated with sustained muscle contractions and abnormal postures
• Common in foot dystonia, cervical dystonia, and blepharospasm
• Often correlates with "off" periods in PD patients

• Restlessness and inability to remain still
• May be confused with motor restlessness or tardive dyskinesia
• Can significantly impact daily functioning

The pathophysiological mechanisms underlying pain in parkinsonian syndromes include:

• Loss of dopaminergic neurons in the substantia nigra affects pain processing
• The basal ganglia play a key role in pain perception and modulation
• Dopaminergic therapy may modulate pain thresholds

• Microglial activation in pain processing regions
• Elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
• Involvement of brainstem pain modulatory pathways

• Thalamic dysfunction affecting sensory processing
• Spinal cord involvement in some cases
• Small fiber neuropathy in certain conditions

• Pain secondary to rigidity and abnormal postures
• Pain from falls and injuries related to postural instability
• Pain from musculoskeletal complications of akinesia

Autonomic Dysfunction

Autonomic impairment is a core feature of parkinsonian syndromes, with significant variations in presentation and severity across different disorders. Autonomic dysfunction often serves as a differential diagnostic feature and may precede motor symptoms in some cases[@goldstein2006].

Autonomic Dysfunction in Progressive Supranuclear Palsy

PSP is characterized by relatively mild to moderate autonomic dysfunction compared to MSA:

• Present in approximately 50-70% of PSP patients
• Typically less severe than in MSA
• May be exacerbated by medications
• Contributes to falls and syncope risk

• Urinary urgency and frequency are common
• Nocturia frequently disrupts sleep
• Less commonly progresses to urinary incontinence

• Very common, often predating motor symptoms
• Related to enteric nervous system involvement
• May respond to dietary modifications and laxatives

• REM sleep behavior disorder is less common than in PD
• Sleep fragmentation is frequent
• Obstructive sleep apnea may be present

MSA is characterized by severe autonomic failure, which is a hallmark feature of the disorder:

• Present in the majority of MSA patients
• Often severe and symptomatic
• Results from failure of sympathetic vasoconstrictor neurons
• May cause recurrent syncope

• Urinary incontinence is a key diagnostic feature
• Detrusor overactivity is common
• Often requires management with anticholinergic medications or intermittent catheterization

• Common in male patients
• Often an early symptom
• May precede motor symptoms by years

• Severe constipation is universal
• Gastroparesis may occur
• Weight loss can be significant

Autonomic dysfunction in PD is generally mild to moderate:

• Orthostatic hypotension affects 30-50% of patients
• Urinary symptoms are common but usually less severe
• Constipation is very common and often early
• Sexual dysfunction may occur

CBS shows variable autonomic involvement:

• Orthostatic hypotension may be present
• Urinary dysfunction occurs in some patients
• Less studied than in other parkinsonian syndromes

Study Objectives

Primary Endpoints

The study aims to systematically characterize:

• Pain Prevalence and Characteristics: Determine the prevalence of different pain types and their clinical features across diagnostic groups
• Autonomic Symptom Burden: Quantify the severity and distribution of autonomic symptoms
• Correlation with Disease Severity: Examine relationships between non-motor symptoms and motor disease severity

Secondary Endpoints

Additional analyses will assess:

• Quality of Life Impact: Evaluate how pain and autonomic symptoms affect functional status and quality of life
• Comparison Across Diagnoses: Compare the profile of non-motor symptoms across PD, PSP, MSA, and CBS
• Treatment Response Patterns: Examine relationships between dopaminergic therapy and non-motor symptom severity
• Biomarker Correlations: Where available, examine correlations with disease biomarkers

Assessment Tools

Pain Evaluation

The study employs validated instruments for comprehensive pain assessment:

• Subjective pain intensity measurement
• 0-100 mm scale
• Quick and widely used

• Disease-specific pain assessment
• Covers seven pain domains
• Validated for PD and adapted for other parkinsonian syndromes

• Comprehensive pain assessment
• Sensory, affective, and evaluative dimensions
• Provides detailed pain characterization

• Screening tool for neuropathic pain
• Ten items assessing sensory descriptors and examination findings
• Helps differentiate neuropathic from nociceptive pain

• Assesses pain severity and interference
• Widely validated across conditions
• Useful for functional impact assessment

Autonomic Assessment

Comprehensive autonomic assessment includes:

• Quantitative measure of autonomic function
• Assesses sudomotor, adrenergic, and cardiovagal function
• Provides severity grading

• Self-administered autonomic questionnaire
• Covers six domains: gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual
• Validated for Parkinson's disease

• Blood pressure and heart rate in supine and standing positions
• Classic test for orthostatic hypotension
• Simple and informative

• Measure of cardiac autonomic modulation
• Reduced HRV indicates autonomic dysfunction
• Non-invasive assessment tool

• Evaluates sudomotor function
• Useful for small fiber neuropathy detection
• Available in specialized centers

Relevance to Treatment Planning

Pain Management Implications

Understanding pain in parkinsonian syndromes has important therapeutic implications:

• Pain that improves with dopaminergic therapy suggests dopaminergic mechanism
• Motor fluctuations may correlate with pain fluctuations
• Continuous dopaminergic stimulation may provide more stable pain control

• Musculoskeletal pain: Physical therapy, exercise, analgesics
• Neuropathic pain: Gabapentin, pregabalin, duloxetine
• Dystonic pain: Botulinum toxin injections, medication adjustments

• Physical therapy and exercise programs
• Occupational therapy for functional adaptation
• Cognitive-behavioral approaches for chronic pain management

Autonomic Symptom Management

Autonomic dysfunction requires specific management strategies:

• Increased salt and fluid intake
• Compression stockings
• Head-of-bed elevation
• Fludrocortisone or midodrine in severe cases

• Bladder training techniques
• Anticholinergic medications (caution in cognitive impairment)
• Intermittent catheterization for severe cases

• High-fiber diet
• Adequate hydration
• Regular exercise
• Osmotic laxatives as needed

Expected Findings and Clinical Impact

Anticipated Study Outcomes

The study is expected to provide:

Clinical Significance

The results of this study will inform:

Cross-References

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy-psp)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy-msa)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome-cbs)
• [Non-Motor Symptoms in Parkinson's Disease](/mechanisms/parkinson-non-motor-symptoms)
• [Autonomic Dysfunction in Neurodegeneration](/mechanisms/autonomic-dysfunction-neurodegeneration)
• [Pain Management in Neurodegeneration](/therapeutics/pain-management-neurodegeneration)
• [Quality of Life in PSP](/diseases/psp-quality-of-life)

Related Research

Key Publications on Pain in Parkinsonian Syndromes

| Study | Year | Key Finding |
|-------|------|-------------|
| Defaye et al. | 2022 | Pain prevalence 40-85% in PD, higher than previously recognized |
| Wu et al. | 2019 | Pain in PSP correlates with disease severity and axial symptoms |
| Chaudhuri et al. | 2010 | Non-motor symptoms bundle includes pain as core feature |

Key Publications on Autonomic Dysfunction

| Study | Year | Key Finding |
|-------|------|-------------|
| Goldstein et al. | 2006 | Autonomic dysfunction helps differentiate MSA from PD |
| Sachdev et al. | 2015 | Autonomic symptoms in PSP correlate with disease progression |
| Khoo et al. | 2016 | Non-motor symptoms in PSP are prevalent and disabling |

Pathophysiology of Pain in Parkinsonian Syndromes

Central Mechanisms

The basal ganglia play a critical role in pain processing. In Parkinson's disease and related disorders, dopaminergic degeneration disrupts normal pain modulation:

Dopaminergic Pain Modulation

• The substantia nigra pars compacta projects to the striatum, which modulates pain perception through thalamic and cortical pathways
• Loss of dopaminergic neurons reduces endogenous pain inhibition
• This explains why dopaminergic medications can sometimes improve pain in PD

• The ventrolateral thalamus receives altered input from the basal ganglia
• This can lead to thalamic pain syndrome (Dejerine-Roussy syndrome)
• Characterized by contralateral hemibody pain, allodynia, and hyperalgesia

• Microglial activation in the substantia nigra and spinal cord
• Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) contribute to central sensitization
• Peripheral inflammation may exacerbate central pain mechanisms

Peripheral Mechanisms

Musculoskeletal Contributions

• Rigid muscles and dystonia create chronic mechanical stress
• Abnormal postures lead to joint degeneration
• Falls and injuries cause persistent pain

• Alpha-synuclein deposition in peripheral nerves
• Autonomic nerve fiber involvement
• Contributes to neuropathic pain components

Classification of Pain in PD

| Type | Description | Prevalence in PD |
|------|-------------|------------------|
| Musculoskeletal | Aching, stiffness, related to rigidity | 40-50% |
| Neuropathic | Burning, tingling, radicular | 20-30% |
| Central | Thalamic, dysesthetic | 10-15% |
| Akathisia | Restlessness, inability sit still | 15-20% |
| Nocturnal | Sleep-related pain, cramps | 30-40% |

Autonomic Dysfunction in Atypical Parkinsonisms

Progressive Supranuclear Palsy

Autonomic involvement in PSP is intermediate between PD and MSA:

Cardiovascular

• Orthostatic hypotension occurs in 20-40% of PSP patients
• Typically milder than MSA
• May worsen with disease progression
• Can contribute to falls and syncope

• Urinary urgency and frequency common
• Nocturia affects up to 60%
• Less severe than MSA but significant impact on quality of life

• Constipation in 50-70% of patients
• Delayed gastric emptying
• May precede motor symptoms by years

• Sweating abnormalities
• Heat/cold intolerance
• May relate to hypothalamic involvement

Multiple System Atrophy

Autonomic failure is a defining feature of MSA:

Neurogenic Orthostatic Hypotension

• Failure of sympathetic vasoconstriction
• Severe drops in blood pressure upon standing
• Can cause syncope, falls, and cerebral hypoperfusion

• Urinary incontinence (often early sign)
• Incomplete bladder emptying
• High post-void residual volumes

• Often presents early in male patients
• May precede motor symptoms

• Laryngeal stridor from vocal cord paralysis
• Sleep-disordered breathing
• Central apneas

Corticobasal Syndrome

Autonomic symptoms in CBS are less prominent:

• Orthostatic hypotension in ~20%
• Urinary urgency common
• Gastrointestinal involvement similar to PSP

Clinical Assessment Strategies

Pain Assessment Batteries

Quantitative Sensory Testing (QST)

• Thermal threshold testing
• Mechanical detection and pain thresholds
• Temporal summation assessment
• Helps distinguish central vs peripheral mechanisms

• PET/SPECT studies show altered pain processing
• Reduced dopamine receptor availability in pain circuits
• Functional MRI during pain tasks

Autonomic Testing

Cardiovascular Autonomic Tests

• Head-up tilt table testing
• 24-hour ambulatory blood pressure monitoring
• Heart rate variability analysis
• Baroreflex sensitivity assessment

• Quantitative sudomotor axon reflex test (QSART)
• Thermoregulatory sweat test
• Skin biopsy for small fiber neuropathy

• Urodynamics
• Post-void residual measurement
• Urethral pressure profiling

Management Approaches

Pharmacological Treatments for Pain

Dopaminergic Agents

• Levodopa may improve pain in some PD patients
• Dopamine agonists have mixed results
• Pain often improves with motor symptom control

• Duloxetine: SNRI with pain-modulating effects
• Amitriptyline: TCA with strong analgesic properties
• Must consider side effect profiles in elderly

• Gabapentin: Calcium channel modulation
• Pregabalin: Similar mechanism, better bioavailability
• Effective for neuropathic components

• Capsaicin cream for peripheral neuropathic pain
• Lidocaine patches
• Opioids: Use cautiously due to side effects and dependency risk

Autonomic Symptom Management

Orthostatic Hypotension

• Increased salt and fluid intake
• Compression stockings
• Head-of-bed elevation
• Fludrocortisone or midodrine
• Droxidopa (Northera) FDA-approved for neurogenic OH

• Anticholinergics (oxybutynin, tolterodine)
• Beta-3 agonists (mirabegron)
• Intermittent catheterization if retention
• Botulinum toxin for detrusor overactivity

• Fiber supplements and laxatives
• Prokinetic agents (metoclopramide)
• Scheduled toileting
• Dietary modifications

Research Implications of NCT05748028

Scientific Value

This observational study addresses critical knowledge gaps:

Epidemiological Data

• Current prevalence estimates vary widely
• Better characterization will inform clinical practice
• May identify subgroups with distinct mechanisms

• Correlation with imaging and biomarker data
• Understanding of pain-autonomic relationships
• May reveal novel therapeutic targets

• Development of standardized assessment tools
• Identification of treatment response predictors
• Foundation for future interventional trials

Integration with NeuroWiki Content

This study relates to several key pages:

• [Parkinson's Disease](/diseases/parkinsons-disease) — core disease mechanism
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — atypical parkinsonism
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) — autonomic failure focus
• [Alpha-Synuclein](/proteins/alpha-synuclein) — pathogenic protein
• [Dopamine](/entities/dopamine) — neurotransmitter involved
• [Neuroinflammation](/mechanisms/neuroinflammation) — common pathway
• [Autonomic Dysfunction](/symptoms/autonomic-dysfunction) — symptom domain

Study Methodology Details

Recruitment Strategy

• Multiple movement disorder centers
• Specialized autonomic testing facilities
• Target enrollment: 200-300 participants

Assessment Timeline

• Baseline comprehensive evaluation
• 6-month follow-up
• Annual reassessment for longitudinal cohort

Data Collection Points

Motor Assessment

• MDS-UPDRS Parts I-III
• Hoehn and Yahr staging
• Timed motor tests

• Non-Motor Symptoms Scale (NMSS)
• Parkinson's Disease Questionnaire (PDQ-39)
• Montreal Cognitive Assessment (MoCA)

• SCOPA-AUT
• Orthostatic vital signs
• Bladder/bowel diaries

• Visual Analog Scale (VAS)
• King's Parkinson's Disease Pain Scale (KPPS)
• McGill Pain Questionnaire
• DN4 for neuropathic features

Expected Impact on Treatment Guidelines

Short-Term Contributions

• Improved awareness of symptom prevalence
• Better assessment practices
• Identification of unmet needs

Long-Term Implications

• Development of targeted therapies
• Personalized treatment approaches
• Biomarker discovery for clinical trials

Conclusion

Pain and autonomic dysfunction represent major challenges in Parkinsonian syndromes. NCT05748028 provides a critical opportunity to systematically characterize these symptoms across disease subtypes. The resulting data will inform clinical management, guide research priorities, and ultimately improve quality of life for patients with Parkinson's disease and atypical parkinsonisms.

References